Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Clidec who wrote (49292)	1/29/1999 10:57:00 AM
From: Andrew G.	Respond to of 119973

My gosh, look at NEOP go! It's up over 58% and still going. News today. Way below 52 wk high biz.yahoo.com Partial story below: Friday January 29, 7:32 am Eastern Time Company Press Release Neoprobe Receives CE Mark Approval in Europe For its neo2000 Gamma Detection System DUBLIN, Ohio--(BW HealthWire)--Jan. 29, 1999--Neoprobe Corporation (Nasdaq/NMS:NEOP - news) today announced it has received notification of official certification from British Standards Institution, the company's Notified Body in the European Union, that the Company has approval to apply the CE Mark under the Medical Devices Directive for the neo2000(TM) Gamma Detection System. The CE Mark approval allows Neoprobe to begin marketing the device throughout the European Union. ''The neo2000 has been strongly accepted by surgeons in the United States. Two major influences for surgeon acceptance have been the simple design and ease of operation which Neoprobe built into this enhanced, innovative product, and the rapidly expanding intraoperative lymphatic mapping (ILM) market,'' stated Matthew Bowman, Neoprobe's Senior Vice President of Marketing & Operations. ''A comparable market response is anticipated for Europe.''